Our results point to CD8 and FAP as potential prognostic biomarkers and demonstrate the heterogeneous expression pattern of CD200 in patients with pancreatic ductal adenocarcinoma. The gene discussed is CD8A; the disease is pancreatic ductal adenocarcinoma.